For $80 million upfront and the promise of more than $1.2 billion in milestones, Novartis has bought the global rights to develop an oral HDAC6 inhibitor from Chong Kun Dang Pharmaceutical.
https://www.pharmalive.com/wp-content/uploads/2023/10/BioSpaceNovartis10-3-2023.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-11-07 10:01:402023-11-07 10:01:40Novartis inks potential $1.3B contract with Korean biotech for small molecule
